Its a pretty understated report but the key takeaways for me...

Its a pretty understated report but the key takeaways for me are:
1. The re-branding was a necessary and important step to establish our new company and put a line through LifeSpot for ever
2. They are close to having a GMP manufacturing capability so wont be reliant on the expensive compounding pharmacy model. This would have been planned prior to the scale up in pod sales. compounding pharmacy was fine for a few pods whilst they were testing it out with clients
3. Progress with Camargo towards the pre-IND meeting which we expect to be probably around March 2022. As i understand it there are usually fixed timeframes around these meetings once you set the process going. After this initial meeting usually have your IND meeting within 60 days so we are well on the way to clinical trials starting
4. Cash burn is incredibly low considering they made an up front payment to Camargo and also paid their annual ASX and insurance costs.

In summary things seem to be tracking along nicely. Still a sleeping giant for now.